Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 14/20 | 0.36 |
| ▸ | ADK | P55263 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.32 |
| ▸ | HTR1A | P08908 | 1/20 | 0.32 |
| ▸ | DRD2 | P14416 | 1/20 | 0.32 |
| ▸ | HTR2A | P28223 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2625323 | 0.84 | HTR1A (0.39) | GRM5ADKALDH1A1HTTHTR1A | |
| SCHEMBL10220350 | 0.70 | HTR1A (0.39) | GRM5ALDH1A1HPGDHTR1ADRD2 | |
| SCHEMBL4072415 | 0.66 | KDM4E (0.42) | GRM5KMT2AALDH1A1MAPTHTT | |
| SCHEMBL13423651 | 0.65 | TDP2 (0.39) | ADKKMT2AALDH1A1MAPTHPGD | |
| SCHEMBL2625305 | 0.64 | ALDH1A1 (0.40) | KMT2AALDH1A1MAPTHPGDTSHR | |
| SCHEMBL12965704 | 0.62 | GRM5 (0.62) | GRM5KMT2AALDH1A1 | |
| SCHEMBL2625325 | 0.61 | HSF1 (0.35) | ADKKMT2AALDH1A1MAPTHPGD | |
| SCHEMBL2669107 | 0.59 | GRM5 (0.58) | GRM5KMT2A | |
| SCHEMBL89125 | 0.59 | L3MBTL1 (0.60) | KMT2AALDH1A1MAPTHPGDHTT | |
| SCHEMBL1746137 | 0.59 | TSHR (0.48) | ADKKMT2AALDH1A1MAPTHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100069357-A1 | PYRIMIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | GENENTECH, INC. (US) | 2010-03-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100069357-A1 | PYRIMIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | MTOR, TYMS, DTYMK | GRM5 2133/4885ADK 142/4885KMT2A 4093/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.